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Abstract Gerstmann-Sträussler-Scheinker (GSS) syndrome is
a fatal autosomal dominant neurodegenerative prionopathy
clinically characterized by ataxia, spastic paraparesis, extrapy-
ramidal signs and dementia. In some GSS familiar cases
carrying point mutations in the PRNP gene, patients also
showed comorbid tauopathy leading to mixed pathologies. In
this study we developed an induced pluripotent stem (iPS) cell
model derived from fibroblasts of a GSS patient harboring the
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Y218N PRNP mutation, as well as an age-matched healthy
control. This particular PRNP mutation is unique with very
few described cases. One of the cases presented neurofibrillary
degeneration with relevant Tau hyperphosphorylation. Y218N
iPS-derived cultures showed relevant astrogliosis, increased
phospho-Tau, altered microtubule-associated transport and cell
death. However, they failed to generate proteinase K-resistant
prion. In this study we set out to test, for the first time, whether
iPS cell-derived neurons could be used to investigate the ap-
pearance of disease-related phenotypes (i.e, tauopathy) identi-
fied in the GSS patient.
Keywords Gerstmann-Sträussler-Scheinker . Induced
pluripotent stem cells . Tau . Cellular prion protein
Introduction
Biomedical research on neurodegenerative diseases with low
prevalence in humans relies on the possibility of analyzing
brain samples only at very late stages of the disease. Thus,
our view of the biochemical or molecular changes during the
disease is partial. This drawback steadily increases with a
faster neurodegenerative progression speed (e.g., in
prionopathies [1] or rapid Alzheimer’s disease [2]). This is
also the case for most sporadic taupathies and in most cases
of frontotemporal lobar degeneration (FTLD) displaying neu-
rofibrillary degeneration [3, 4]. This limitation impedes the
study of early onset changes in asymptomatic patients, making
it impossible to investigate illness evolution, therefore ham-
pering biochemical/molecular studies and drug discovery [5].
Gerstmann-Sträussler-Scheinker syndrome (GSS) is a rare
autosomal dominant neurodegenerative prionopathy clinically
characterized by a wide spectrum of manifestations including
but not limited to ataxia, spastic paraparesis, extrapyramidal
signs and dementia [6, 5]. Most GSS patients have the P102L
mutation in the cellular prion protein (PrPC) gene (PRNP)
located in the short arm of chromosome 20 [5]. Cases of rapid
progressive forms of GSS are rare [7] with an average duration
after clinical diagnosis of 5–6 years (from 6 months to
13 years) [8, 5]. Histopathological examination of post-
mortem GSS brains has revealed abnormal misfolded prion
(PrP) aggregates in the form of unicentric and multicentric
deposits in the cerebellum and cortical gray matter [5]. In
addition, western blot analysis of aggregated PrP is distin-
guished by the presence of truncated protein fragments rang-
ing between 6 and 10 KDa and a variable number of bands of
higher molecular weight [9]. Parallel to this particular PrP
deposition, pathological features characteristic of other neuro-
degenerative diseases such us parkinsonism or Alzheimer’s
disease have been observed in some GSS patients [5].
Indeed, an increase in hyperphosphorylated Tau is frequently
observed in the pathological analysis of brains from GSS pa-
tients carrying PRNP mutations P102L [10], P105L [11],
A117V [12], V176G [13], F198S [14, 15], Q217R [16, 15]
and Y218N [17]. Although it has been shown that PrPC with
the P102L mutation display an increased binding to Tau [18],
the role of these point mutations in the development of neu-
rofibrillary degeneration is unknown. Nevertheless, in some
P102L GSS cases with increased levels of p-Tau, the distribu-
tion of p-Tau tangles close to PrP deposits suggesting an active
participation of PrP in the generation of p-Tau [10].
Due to the above-mentioned restrictions in this study we
explored the usefulness of an induced pluripotent stem (iPS)
cell model derived from somatic cells from a GSS patient. iPS
cell technology is a tool for basic and translational research
through generating in vitro models of disease-relevant cells
reprogrammed directly from patients [19–21]. This approach
has been shown to be particularly useful in the case of con-
genital or early-onset monogenic diseases [22] as well as other
neurodegenerative diseases [23]. iPS cells have been generat-
ed from patients with Alzheimer’s [24], Parkinson’s [25, 26],
Hungtinton’s [27] diseases as well as FTLD [28],
Amyotrophic Lateral Sclerosis (ALS) [29] and several others.
However, there are no reports of iPS cell lines derived from
patients with familial prionopathies.
In this study, we generated iPS cells from dermal fibro-
blasts of a family member of the Y218NGSS patient described
by Alzualde and colleagues [17] and differentiated them into
neurons using two previously published procedures [30, 31].
To date, very few individuals have been reported carrying this
mutation [17, 32]. We were interested in this familiar since the
Y218N patient displayed widespread neurofibrillary degener-
ation in the brain [17]. Results determined that although dif-
ferentiated Y218N iPS cells were not able to spontaneously
generate or propagate human prions, Y218N-derived cultures
showed relevant astrogliosis and cell death. In addition, dif-
ferentiated Y218N-derived neurons displayed high levels of p-
Tau, thus recapitulatingmost of the neuropathological features
reported in the patient [17].
Material and Methods
Case Patient The index case and the younger sister was ex-
amined at the Cognitive Disorders Unit at Donostia Hospital.
The clinical report of the family and the Y218N patient can be
seen in [17]. Dermal fibroblasts were obtained from the youn-
ger sister of the Y218N patient (54 years old in 2010) after
having made complaints of poor concentration, apathy, emo-
tional lability, and increasing difficulties in planning and
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executing actions. She had previously been diagnosed with
and treated for a depressive illness, and the neuropsychologi-
cal examination revealed slight memory dysfunction in re-
trieval, language impairment followed by anomia with pre-
served verbal comprehension, and executive dysfunction.
The Mini Mental State Examination (MMSE) score was 23/
30. Magnet ic resonance imaging showed s l ight
frontotemporal atrophy and EEG analysis revealed intermit-
tent frontotemporal delay. An additional EEG, 6 months later,
showed slow background activity in the patient, with intermit-
tent delta waves in the left hemisphere. 10 months after onset,
she had language difficulties, with impairment in semantic
knowledge, and MMSE score dropped to 13/30.
Generation of iPS Cells All experiments were performed
under the guidelines and protocols of the Ethical Committee
for Animal Experimentation (CEEA) of the University of
Barcelona. All procedures adhered to internal and EU guide-
lines for research involving derivation of pluripotent cell lines.
All subjects gave informed consent for the study using forms
approved by the Ethical Committee on the Use of Human
Subjects in Research at Hospital Donostia in San Sebastián,
Spain. Generation of iPSC lines was approved by the
Advisory Committee for Human Tissue and Cell Donation
and Use, by the Commission on Guarantees concerning the
Donation and Use of Human Tissues and Cells of the Carlos
III Health Institute, Madrid, Spain (Ref: 589, 1/21/2015). All
procedures were done in accordance with institutional guide-
lines and the cell lines have been (or will be) deposited at the
Banco Nacional de Lineas Celulares (BNLC, ISCIII) follow-
ing the Spanish legislation. Fibroblasts from a healthy indi-
vidual and from the Y218N GSS patient were infected with
retroviruses carrying human cDNA coding for KLF4, SOX2,
and OCT4, with or without the addition of c-MYC as previ-
ously described [33]. Fibroblasts were maintained in DMEM
(Sigma) supplemented with 10% FBS (Life Technologies)
and 1% Pen/Strep solution (Life Technologies) before infec-
tion. After infection, fibroblasts were plated on irradiated hu-
man foreskin fibroblasts (HFF, ATCC) and maintained with
hESC medium for 4–12 weeks until iPS cell colonies ap-
peared. Several clones from each cell line were obtained and
validated. Y218N patient (FH10) and parallel control (FHB1)
iPS cell clones were analyzed in details (see below).
Characterization of iPS Cell Lines AP staining was per-
formed using the Alkaline Phosphatase Blue Membrane
Substrate Solution (Sigma). For immunocytochemistry, cells
were grown onHFF feeder layers for 6–10 days and then fixed
in 4% PFA for 10 min. After embryonic bodies (EB) forma-
tion, differentiation into the 3 germ layers was performed. For
endoderm, EBs were plated on 6-well plates treated with
Matrigel (BD Biosciences) for 1 h at room temperature, and
maintained for 28 days with EB medium. The same procedure
was used for mesoderm, but instead using EB medium with
0.5 mM of ascorbic acid. For ectoderm differentiation, EBs
were maintained in suspension for 10 days with Neurobasal
medium containing N2, B27 and FGF2 (N2B27 medium),
prepared as previously described [26]. EBs were then plated
on 6-well Matrigel-coated plates and maintained for 21 days
with N2B27 medium without FGF supplementation.
Differentiated cells were fixed in 4% PFA for 10 min. For
nuclear DAPI staining (Invitrogen), 0.5 μg/ml was used.
The slides were mounted with PVA:DABCO mounting medi-
um. Images were acquired with an SP2 confocal system
(Leica) and analyzed with ImageJ™ software. RT-qPCR anal-
ysis was performed as previously described [26]. All results
were normalized to the average expression of Glyceraldehyde
3-phosphate dehydrogenase (GAPDH). Transcript-specific
primers used are shown in Supplementary Table 1.
For karyotyping, iPS cells were grown on Matrigel and
treated with colcemid (Life Technologies) at a final concen-
tration of 20 ng/ml. Karyotyping analysis was carried out by
Prenatal Genetics S.L. (Barcelona). For promoter methylation,
testing reprogramming gene integration and sequencing to
confirm that patient iPS cells were carrying mutations in
PRNP gene, DNA was isolated using the QIAamp DNA
Mini Kit (QIAGEN) following the manufacturer’s instruc-
tions. Bisulfit conversion of the promoters was carried out
using the Methylamp DNA modification kit (Epigentek).
Five clones of each promoter for each cell line were analyzed
by sequencing. The primers used for testing gene integration
are shown in Supplementary Table 1.
iPS Cell Differentiation to Neural Cells In this study, two
protocols were used to differentiate the iPS cells. In the first
protocol, iPS cell colonies were mechanically passaged onto
Matrigel-coated 6-well plates. 24 h later the mTeSR™ was
replaced by DDM neural induction medium [34, 35] with
the addition of the ALK inhibitor, SB431542 at 10 mM for
4 days (Tocris) and the BMP inhibitor, LDN-193189 at
100 nM (Miltenyi Biotech) for 12 days. Cells were propagated
in this medium for 3 weeks. At about 24 days in vitro, cells
were dissociated and plated onto wells coated with poly-L-
lysine (33.3 mg/ml, BD) and laminin (3.3 mg/ml, BD), and
the mediumwas changed to N2B27 medium. For immunoflu-
orescence, neurons were dissociated with Accutase (Sigma)
and replated on glass coverslips coated with poly-L-lysine and
laminin. Characterization was done as previously described
[36].
In the second procedure, spherical neural masses (SNMs)
were obtained as previously described [37]. SNMs were fixed
in 4%phosphate buffered paraformaldehyde (PFA) for 2 h and
characterized by immunostaining. For nuclear DAPI staining
(Invitrogen), 5 μg/ml was used. Mounting medium and imag-
ing analysis were performed for in vitro differentiation testing.
SNMs obtained from control and Y218N iPS cells, having
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been maintained in suspension, were then plated on slide-
flasks, 6-well plates, 35 mm ∅ plates or 10 mm ∅ plates all
previously treated with Matrigel for 1 h at room temperature,
and differentiated for 3, 6 or 9 weeks with N2B27 [26], with-
out FGF supplementation to obtain neural cultures. The cor-
rect differentiation was assessed by immunostaining.
Antibodies used are shown in Supplementary Table 2. For
nuclear DAPI staining (Invitrogen), 0.5 μg/ml was used.
The slides were mounted with Mowiol mounting medium.
RT-PCR ProtocolQuantitative real time PCRwas performed
on total RNA extracted with mirVana’s isolation kit (Ambion)
from differentiating iPS cells. Purified RNAs were used to
generate the corresponding cDNAs, which served as PCR
templates for mRNA quantification. Quantitative RT-PCR as-
says were performed in duplicate on cDNA samples obtained
from the retro-transcription reaction diluted 1:20 in 384-well
optical plates (Kisker Biotech) using the ABI Prism 7900 HT
Sequence Detection System (Applied Biosystems). The reac-
tions were carried out using 20xTaqMan gene expression as-
says for genes and 2xTaqMan Universal PCR Master Mix
(Applied Biosystems). The reactions were conducted using
the following parameters: 50 °C for 2 min, 95 °C for
10 min, 40 cycles at 95 °C for 15 s and 60 °C for 1 min.
The fold change was determined using the eq. 2-ΔΔCT.
Primers used in iPS cell differentiation experiments and Tau
R3/R4 analysis can be seen in Supplementary Table 3.
Sample Collection and Proteinase K Treatment Samples of
control and Y218N differentiating cultures were collected at
several differentiation times and were homogenized in 10%
lysis buffer (100 mM NaCl, 10 mM EDTA, 0.5% Nonidet
P-40, 0.5% sodium deoxycholate, and 10 mM Tris, pH 7.5).
Debris were removed with low-speed centrifugation at
3000×g for 10 min, and the supernatants were collected. To
detect the presence of Proteinase K (PK)-resistant PrP in the
supernatant, homogenates were digested with a final concen-
tration of 10–50μg/ml PK at 37 °C for 60min prior to western
blot analysis using 3F4 antibody against PrPC. To evaluate the
PK resistance of protein samples from the original Y218N
patient [17], type I sporadic Creutzfeldt-Jakob disease
(sCJD) and Type II sCJD brain homogenates were also proc-
essed in parallel. PK digestion was terminated by adding
Laemmli buffer and heating the samples at 100 °C for 10 min.
Western Immunoblot Samples from different differentiation
stages from iPS cells to neuronal cultures were processed for
western blot, including human post-mortem samples and con-
trol cultured cells. The collected samples were homogenized
in (10% wt/vol) of 50 mM Tris-HCl, pH 7.4/150 mM
NaCl/0.5% Triton X-100/0.5% Nonidet P-40 and a mixture
of proteinase inhibitors. After this, samples were centrifuged
at 15,000 x g for 20min at 4 °C. The resulting supernatant was
normalized for protein content using BCA kit (Pierce). Cell
extracts containing Laemmli buffer were boiled at 100 °C for
10 min, followed by 8–10% SDS electrophoresis, then
electrotransferred to nitrocellulose membranes for 2 h at
4 °C. Membranes were then blocked with 5% not-fat milk in
0.1 M Tris-buffered saline (pH. 7.4) for 2 h and incubated
overnight in 0.5% blocking solution containing primary anti-
bodies. After incubation with peroxidase-tagged secondary
antibodies (1:2000 diluted), membranes were revealed with
ECL-plus chemiluminescence western blot kit (Amershan-
Pharmacia Biotech). In our experiments, each nitrocellulose
membrane was used to detect p-Tau (AT-8 and PHF1 antibod-
ies), Actin, Tubulin as protein loading controls. A list of the
antibodies used in these experiments can be seen in
Supplementary Table 2.
Densitometry and Statistical Processing For quantification,
developed films were scanned at 2400 × 2400 dpi (i800
MICROTEK high quality film scanner), and the densitometric
analysis was performed using Quantity One Image Software
Analysis (Biorad). Statistical analysis of the obtained data
(RT-qPCR and Western blot) was performed using
Bonferroni post hoc test (Multiple comparison test) using
GraphPad Prism 6 (Mac OsX, Grahpad). Data are presented
as mean ± standard error of the mean (S.E.M.). Differences
between groups were considered statistically significant be-
tween **** P < 0.001, *** P < 0.01 and ** P < 0.05.
Immunohistochemistry Differentiating iPS cell cultures
were fixed in 4% PFA at different days in culture and then
permeabilized with 0.1% Triton X-100 (Sigma) in 0.1M PBS.
After fixation, and extensive rinsing with 0.1 M PBS, cultures
were blocked with 10% FBS in 0.1 M PBS prior to incubation
with primary antibodies (see Supplementary Table 2). After
incubation with primary antibodies, cells were incubated with
the pertinent Alexa Fluor-tagged secondary antibodies
(Alexa-488 goat anti-mouse or Alexa-568 goat anti-rabbit)
(Invitrogen-Life Technologies). Finally, cells were stained
with 0.1 μM DAPI (Sigma) diluted in 0.1 M PBS, mounted
onMowiol, and viewed using anOlympus BX61 fluorescence
microscope, Zeiss LSM or a Leica SP5 confocal microscopy.
Corrected Total Cell Fluorescence (CTCF) Measurement
CTCF levels of p-Tau (red channel) and MAP2 (green chan-
nel) were measured in 150 (Y218N) and 165 (control) identi-
fied neurons after 21 days of differentiation using ImageJ™
software following published instructions http:/ /
sciencetechblog.com/2011/05/24/measuring-cel l -
fluorescence-using-imagej/. See also [38] for details. CTCF
values were determined using the following formula. CTCF
= Integrated Density – (Area of selected cell x Mean
fluorescence of background readings). Statistical analysis of
the obtained data was performed using Mann-Whitney U test
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using GraphPad Prism 6 (Mac OsX, Grahpad). Differences
between groups were considered statistically significant be-
tween **** P < 0.001.
Mitochondrial Movement Analysis in iPS Cell-Derived
Neurons SNM-derived neurons were incubated after 21 days
of differentiation with MitoTracker (Molecular Probes) and
filmed using a Leica TCS SP2 confocal microscope (Leica)
equipped with a 63× immersion oil objective. Time-lapse se-
ries of image stacks composed of 10 images (512 × 512
pixels) were taken every 3 s over 10 min. Movies were gen-
erated at 10 frames per second. Forty-two axons were regis-
tered and analyzed in each group recorded. In all cases, a
mitochondrion was considered motile when it moved more
than 0.5 μm during 1 min of recording. Distances and speeds
of retrograde and anterograde transport were measured, and
no tracking pluging was used. ImageJ™ software was used to
quantify mitochondrial movement. For each mitochondrion
movement, the minimum displacement and the average over
time were plotted. Statistical analysis of the obtained data was
performed usingMann-Whitney U test using GraphPad Prism
6 (Mac OsX, Grahpad). Differences between groups were
considered statistically significant between *** P < 0.01 and
** P < 0.05.
Infectivity Assay Brain homogenates (10% in sterile PBS)
were made fresh the day of the infection. One aliquot was kept
frozen at −80 °C to repeat the exposure 72 h after the first
infection, as described [39]. Representative samples were tak-
en to confirm the presence of PK-resistant PrP in the homog-
enates, following digestion with 50 μg/ml for scrapie (263 K)
and Creutzfeldt-Jakob disease (CJD) brains and 12.5 μg/ml
for the Y218N brain [40]. Control and Y218N forebrain neu-
ronal cultures were infected at early (30–40) and middle (60–
80) differentiation times. Neurons were replated 5–6 days be-
fore the experiment. The culture supernatant was replaced by
fresh media containing 10% brain homogenate (day 1) and
this was repeated 72 h later (day 3). Two days later, fresh
medium (without inocula) was added without removing the
supernatant. At day 10 post-inocula (dpi) the entire medium
was replaced and the cells were washed several times with
sterile PBS before adding fresh Neurobasal containing B27
and N2 supplements. Medium was replaced every other day
for the first 2 weeks and then twice a week until cells were
collected or fixed for analysis, ~2 months later. All experi-
ments were performed in a Biosafety level 3 security
laboratory.
Results
Generation and Characterization of Y218N GSS Patient-
Specific iPS Cells Fibroblasts were reprogrammed at early
passages (5–7) through the retroviral delivery of SOX2,
KLF4, OCT4, and c-MYC to generate up to 5 independent
iPS cell lines for each individual (Fig. 1). We selected clones
displaying embryonic stem cell-like morphology and positive
AP staining (Fig. 1a). 5 clones representing each individual
were chosen to be thoroughly characterized and shown to be
fully reprogrammed, as judged by demethylation of OCT4
and NANOG promoters (Fig. 1b), the silencing of the
reprogramming transgenes (Fig. 1c), activation of endogenous
pluripotency-associated factors (Fig. 1c), expression of
pluripotency-associated transcription factors and surface
markers (Fig. 1d), pluripotent differentiation ability in vitro
and/or in vivo (Fig. 1f), and karyotype stability after more than
15 passages (Fig. 1e). Mutation analysis confirmed that iPS
cells and their derivatives bore the mutation Y218N present in
the patient fibroblasts (Fig. 1g).
Late Neuronal Maturation, Increased Reactive
Astrogliosis and Absence of PrP Generation in Y218N-
Derived iPS Cell Cultures Control and Y218N-derived iPS
cells were differentiated into neural cells using two well-
characterized procedures (see Methods). Neural induction
was fast and efficient using both protocols (Fig. 2) and the
cells sequentially expressed typical markers of neural progen-
itors, neuroblasts and mature neurons (Fig. 2b, f). In our first
approach (Fig. 2a-d), taking into account morphology and
marker expression, we established three differentiation stages:
early (≈ 60 DIV), middle (≈ 60–120 DIV) and late (≈ 120–210
DIV) (Fig. 2a). Two weeks after neural induction, cultures
were composed mainly of neural progenitors co-expressing
SOX2 and NESTIN with a few differentiating neuroblasts
(class III β-tubulin (TUJ1)-positive). By 4 weeks many
neuroblasts and young neurons expressed PAX6 and the vast
majority expressed Doublecortin (DCX) and Ubiquitin-
protein ligase E3A (UBE3A) proteins (Fig. 2b). From the third
month onwards, differentiating neurons expressed the mature
post-mitotic neuronal marker NeuN (RBFOX3). In parallel
and as also reported in vivo [41], PrPC expression increased
progressively over time during differentiation (Fig. 2c–d).
In the second protocol (Fig. 2e-h), control and Y218N-iPS
cells were also differentiated to pure masses of neural precur-
sors using a previously described protocol that involves the
formation of EBs and the culture of neural precursor cells to
form SNMs, whom can be expanded and differentiated into
mature neurons after several weeks using neuronal induction
medium (Fig. 2e). In these conditions, SNMs derived from
control and Y218N-iPS cell lines homogeneously expressed
neural progenitor markers such as PAX6, NESTIN, and
SOX2, as well as the proliferation marker Ki67 (Fig. 2f).
Furthermore, when iPS cell-derived SNMs were cultured in
neuronal induction medium supplemented with N2 and B27,
differentiation into mature neurons was evident within 3 to
5 weeks (Fig. 2f). After about 3 weeks in neuronal medium,
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the cultures formed dense MAP2 and TUJ1-positive neuronal
networks (Fig. 2f) in presence of astroglial cells (not shown).
No mixed genotypes (GFAP +MAP2 or TUJ1 double labeled
cells) were observed. As observed in the first approach, PrPC
was clearly present throughout neural differentiation
(Fig. 2c,g, Supplementary Fig. 1). However, no detectable
Fig. 1 Generation and characterization of iPS cells. (a) Control (cell
line FHB1) and GSS-Y218N-iPS cell (cell line FH10) stained for AP
activity. (b) Bisulphite genomic sequencing of the OCT4 and NANOG
promoters showing demethylation in FHB1 and FH10 (Y218N) cell lines.
(c) RT-qPCR analyses of the expression levels of retroviral-derived
reprogramming factors (transgenic) and endogenous expression levels
(endogenous) of the indicated genes in FHB1 (two clones) and Y218N-
iPS cells (cell line FH10, 2 clones). (d) Low fluorescence photomicro-
graphs of representative colonies of FHB1 and FH10 (Y218N) stained
positive for the pluripotency-associated markers OCT4, NANOG and
SOX2 (green), SSEA3, TRA-1-81 and SSEA4 (red). (e) Normal karyo-
types of FHB1 and FH10 (Y218N) at passage 20. (f) Immunofluorescence
analyses of FHB1 and FH10 (Y218N) iPS cells differentiated in vitro
show the potential to generate cell derivatives of all three primary germ
cell layers including ectoderm (stained for TUJ1, green), endoderm
(stained for α-fetoprotein, green, and FOXA2, red) and mesoderm
(stained for smooth muscle actin, SMA, red). (g) Direct sequence of
genomic DNA from Control (cell line FHB1) and GSS patient (FH10
(Y218N)) identifying the PRNPY218N mutation. Scale bars in a, d and
f = 50 μm
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PK-resistant PrP was observed in protein extracts treated with
the enzyme in the Y218N and control-derived neurons gener-
ated with either protocol (Fig. 2d,h), in contrast to brain ex-
tracts from Y218N GSS or Type 1–2 CJD patients (Fig. 2h,
Supplementary Fig. 2).
We next examined the transcriptional profile of neural cul-
tures determined by RT-qPCR from early to late culture stages
(Fig. 3a) and observed significant differences between control
and Y218N cultures, particularly at the late stage (>120 days).
While there were no differences in early progenitor markers
such as NES and SOX2, which showed a similar time-
dependent downregulation in both genotypes, a few neuronal
transcripts were lower in the Y218N cultures early on, like
MAP2 and CALB. At the late stage (>120 days), there was a
robust increase in GFAP mRNA and a concomitant decrease
in mature neuronal markers including MAPT and VGLUT1
mRNAs in Y218N cultures compared to controls. Next, these
mRNA changes were checked by immunohistochemistry and
cell counts (Fig. 3b, d). Cell counts revealed that the relative
percentage of DCX and GFAP expressing cells was not sig-
nificantly different between control and Y218N cultures (data
not shown). Thus, the transcriptional increase in GFAP ex-
pression most likely due to a greater expression in reactive
astroglial cells (Fig. 3c). Indeed, detailed analysis of
immunoreacted cells revealed high content of GFAP forming
thick fascicles in hypertrophic reactive astroglial cells at the
late stage of Y218N cultures (Fig. 3c). Lastly, nuclear staining
analysis in differentiating cultures revealed increased chroma-
tin condensation and apoptosis in the Y218N at the late stage
(Fig. 3d).
Increased tau Phosphorylation in Y218N-Derived
Neurons in Vitro As indicated above, clinical and histopath-
ological examination of the GSS patient carrying the Y218N
PRNP mutation displayed relevant neurofibrillary degenera-
tion with p-Tau deposits in several brain regions [17].
Therefore, we explored putative changes in Tau expression
and phosphorylation in differentiating cultures (Fig. 4,
Supplementary Figs. 3 and 4). As indicated above, MAP2
andMAPTmRNA levels decreased in Y218N-derived cultures
compared to controls suggesting delayed neuronal differenti-
ation (Fig. 3). This was corroborated analyzing the appearance
of the two Tau-splicing forms (4R and 3R) in differentiated
cultures (Fig. 4a). RT-qPCR analysis demonstrated a delayed
appearance of the 4RTau form compared to 3RTau in Y218N-
derived cultures (Fig. 4a). This was corroborated by the bio-
chemical analysis of the acetylated form of Tau at lysine 280
(K280-(ac)) Tau during the differentiation (Fig. 4b,
Supplementary Fig. 4). This acetylated form is associated with
Tau 4R [42, 43]. K280-(ac) Tau levels were constant in
control-derived cultures from 15 to 45 DIV. However,
Y218N cultures showed increased levels of K280-(ac) Tau
between 15 to 41 DIV, following changes of Tau 4R
(Fig. 4b, Supplementary Fig. 4). In parallel, biochemical de-
tection of p-Tau during differentiation demonstrated the in-
crease in p-Tau (detected by AT8 and PHF1 antibodies) in
Y218N-derived neurons compared to control without relevant
changes in PrPC protein levels (Fig. 4b,c, Supplementary
Fig. 3).
Next, we developed a CTCF analysis of p-Tau in identified
MAP2-positive neurons (Fig. 4d,e). First we counted the total
number of MAP2 and p-Tau-positive neurons in Y218N- and
control-derived cultures. As suggested above with RT-qPCR,
the total number of MAP2 and p-Tau double-positive cells
was lower in Y218N-derived cultures (Fig. 4d,e). In addition,
the relative percentage of double-labeled p-Tau/MAP2 neu-
rons was also higher in Y218N-derived neurons. Changes in
p-Tau level in differentiated neurons were also corroborated
by the CTCF analysis of p-Tau in double-labeled p-Tau/
MAP2-immunoreactive neurons (Control: 1566 ± 214.4;
Y218N: 4357 ± 422.1; mean ± S.E.M. P < 0.0001, Mann-
Whitney U test). Indeed, the ratio of p-Tau/MAP2 fluores-
cence was higher in Y218N-derived neurons compared to
control-derived neurons (Control: 0.27 ± 0.02; Y218N:
0.680 ± 0.02; mean ± S.E.M. P < 0.0001, Mann-Whitney
U = 2628) (Fig. 4e,f). Unfortunately, electron microscopy
analyses failed to identify neurofibrillary tangle formation in
Y218N differentiated neurons (not shown). Similar biochemi-
cal observations were also made using the direct cortical dif-
ferentiation protocol (Supplementary Fig. 5). In conclusion,
cultures derived from Y218N mutant iPS cells recapitulated
in vitro several pathological features of the GSS patient, such
a s r e a c t i v e a s t r o c y t o s i s , c e l l d e a t h a nd Ta u
hyperphosphorylation.
Impaired Mitochondria Movement in Y218N-Derived
Neurons The effects of Tau hyperphosphorylation in sev-
eral epitopes on mitochondria movement have been dem-
onstrated in Alzheimer’s disease [44, 28]. We checked
the minimum and the mean velocity of identified mito-
chondria (Fig. 5). Results showed a decrease in both
measurements in Y218N cultures compared with control
(0.052 ± 0.014 (control, n = 111) vs 0.014 ± 0.006
(Y218N; n = 105); mean ± S.E.M., Min. velocity in
μm/s; P = 0.0004; Mann-Whitney U value =4688.
0.310 ± 0.038 (control, n = 111) vs 0.1302 ± 0.014
(Y218N; n = 105); Mean ± S.E.M. Mean velocity in
μm/s; P = 0.0484; Mann-Whitney U value =4921)
(Fig. 5b).
Infectivity Assays In order to examine susceptibility to prion
infection, Y218N- and control-differentiated cultures were ex-
posed for 10 days to brain homogenates prepared from a spo-
radic CJD and from a GSS Y218N brain (Fig. 6a,b). Western
blot analyses of the cultures showed the presence of PK-
resistant PrP forms but only up to 2 weeks after removal of
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the inocula, indicating lack of prion infectivity (and propaga-
tion) in these conditions (Fig. 6c). A similar signal was observed
in cultures infected with 263 K, a hamster scrapie prion strain
which does not propagate to human cells (data not shown).
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Despite the absence of PK-resistant PrP in the cultures after two
weeks, we observed some phenotypic changes that were more
prominent in mutant neurons. In particular, we found a promi-
nent redistribution of Tau signal with enhanced localization in
the soma and proximal neurites in Y218N neurons exposed to
either GSS or CJD inoculates was found (Fig. 6d,e).
Discussion
In the present study we have developed, for the first time, an
iPS cell model of a familial human prionopathy. The donor
GSS patient carrying the Y218N PRNP mutation showed rel-
evant gliosis, cell death, massive deposits of PrP and neurofi-
brillary degeneration in different brain regions [17].
Fig. 3 Transcriptional profile of maturating iPS cell cultures. (a)
Quantitative RT-PCR transcriptional profile of control and mutant cell
cultures at the three maturation stages. Bars represent the
mean ± S.E.M. of 2–4 time points for each stage from at least 2 indepen-
dent differentiations. Data are presented as mean ± standard error of the
mean (S.E.M.). Differences between groups were considered statistically
significant ****P < 0.001, *** P < 0.01 and **P < 0.05. Bonferroni post
hoc test. (b) Representative immunofluorescence microphotographs of
PrPC, DCX and GFAP expression at the three differentiation stages. (c)
Higher power image of GFAP positive cells at mid differentiation stage.
(d). Quantification of apoptotic nuclei (% over total Hoechst). ***
P < 0.01, Bonferroni post hoc test. Scale bars in b = 100 μm and
c = 10 μm
Fig. 2 Neural differentiation of FHB1 and FH10 (Y218N) iPS cells.
IPS cells from control (FHB1) and Y218N (FH10) GSS patient were
differentiated using two procedures (a and e) (see Methods for details).
(b)Low power photomicrographs of representative colonies of FHB1 and
FH10 (Y218N) stained positive for SOX2, Nestin, DCX, TUJ1, PAX6,
UBE3A antigens at different stages of maturation. (c)Western blot char-
acterization of PrPC expression in differentiating iPS cell cultures. (d)
Example of the Western blot experiments illustrating the absence of
PK-resistant PrPC in FH10 (Y218N) cultures. (e) Low power photomicro-
graphs of representative colonies of FHB1 and FH10 (Y218N) stained
positive for Nestin, Ki67, SOX2, TUJ1, PAX6 and GFAP antigens. (g)
Western blot characterization of PrPC expression in iPS cells (passage 20)
and SNMs (passage 3). (h)Western blots illustrating the absence of PK-
resistant prion in FHB1 and FH10 (Y218N) in brain extracts from the GSS
patient and two CJD (Type I and II) samples. Scale bars in b and
f = 50 μm
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Surprisingly, the presence of the Y218N mutation in other
family member belies atypical parkinsonism phenotype in-
stead of neurofibrillary degeneration [32]. Indeed, in parallel
with the classical signs of GSS-associated degeneration, other
clinical presentations, such as Alzheimer ’s-type,
frontotemporal-like dementia, parkinsonism, and atypical
psychiatric disorders, have all been reported (e.g., [45]).
These different clinical manifestations have also been found
in family members with the same PRNP mutation, attributed
to the distinct abnormal isoforms of prion protein and poly-
morphisms at codon 129 [46, 47]. In fact, in this case the two
GSS patients differ at the codon 129 polymorphism (129MV
[32] and 129VV in [17]), which may contribute to clinical
differences between cases.
We used two different well-characterized procedures to dif-
ferentiate the iPS cells into neurons [34, 26]. The first was
directed to obtaining forebrain cortical neurons [34] and the
second one was directed to maintaining regulated develop-
mental steps during neural development [26]. With both pro-
tocols we obtained similar results being able to determine that
Y218N-derived cultures showed relevant GFAP reactivity, cell
death, neuronal Tau redistribution, elevated p-Tau levels and
changes in mitochondrial trafficking. Despite being unable to
reproduce the spontaneous generation of PK-resistant forms
or enabling prion propagation after inoculation in Y218N-iPS
cell derived cultures, the differentiated neural cells recapitu-
lated most of the pathological features observed in the GSS
patient’s brain. In this way, these Y218N-derived cultures
could be used as an in vitro platform for neurodegenerative
studies in familial prionopathies with the aim of characterizing
the role of particular PRNP mutations in comorbid taupathies
and cell death.
Unfortunately, Y218N cells did not generate PrP spontane-
ously and they were unable to propagate human prions (CJD
and Y218N GSS prions) in vitro. This was disappointing but
certainly not fully unexpected given that it has never been
possible to propagate infectivity in primary neurons with hu-
man prions. Furthermore there are no studies of Y218N PrP
propagation in vivo in contrast to other human mutations: i)
P102LGSS human prion in P101Lmice [48], ii) A117VGSS-
derived human prion inoculum in AV117 PRNP mice [49] and
iii) P102L, A117V or F198S PRNP mutations in bank voles
[50].
Concerning the absence of endogenous prion genera-
tion in Y218N-derived neurons we might hypothesize, in
a simplistic manner, that current in vitro times are not
long enough for the endogenous generation of human
PrPres, considering the clinical onset and evolution of
the GSS patient. However, we believe that the current
scenario is not as simple, and that other, as yet un-
known factors with key functions in protein misfolding
and propagation may be absent from our cultures.
In vitro prion propagation (of mostly mouse adapted
strains) has been developed in neural and non-neural
cell lines [51], primary neuronal cultures [52], cerebellar
organotypic slices [53], and, with some controversy, in
neurospheres (e.g., [54]). However, human prions have
not been propagated in neuronal cultures to date. In
fact, a single study of Ladogama et al. reported the
transmission of human prions but using neuroblastoma
cells [55]. In addition, the propagation of human strains
was more successful when prions had been previously
adapted to mice (e.g., M1000 [56]). Although endoge-
nous expression levels could be relevant, we cannot rule
out the participation of other non-neuronal cells
(microglial cells) and inflammatory processes in protein
misfolding and propagation [57] which did not fully
develop in our iPS cell cultures, in contrast to other
3D organotypic approaches that could be assayed in
future experiments [58].
In our study, the differentiation of Y218N-derived iPS cells
was protracted. It is well known that appropriate temporal and
transcriptional levels of PRNP are required for the correct
differentiation of human embryonic stem cells [59] as well
as other neural stem cells in vivo [60] and in vitro [61]. In
fact, early attempts to ablate PRNP in mice using constitutive
promoters and large PRNPmutations were not viable because
PRNP expression starts around E7.5 in neural tissue [62].
Indeed, PrPC is involved in several neural and non-neural
developmental functions and its absence either delays or in-
terferes with cell proliferation and maturation [63–65].
Although a clear explanation of the physiological impact of
the Y218N mutation in these processes remains elusive, the
mutation might induces aberrant folding of the protein [66],
which may impair neuronal differentiation. In fact, in our ex-
periments, mutant neurons showed decreasedmRNA levels of
CALB, VGLUT1 and MAP2 compared with control cells. In
addition, Y218N-derived neurons showed very low numbers
of Ca2+ transients analyzed by Fluo4-AM (data not shown).
Fig. 4 Delayed MAPT maturation and increased p-Tau in Y218N-
derived neurons. (a) Histograms illustrating RT-qPCR results
(mean ± S.E.M.) of Tau 3R/Total tau; Tau 4R/Total and Tau 3R/4R ratios
in FHB1 and FH10 (Y218N) iPS cell cultures during differentiation at 15,
21 and 41 days in vitro. Asterisks in the right graph indicate P < 0.05,
Bonferroni post hoc test; Mean Diff. -0.756; 95% confidence inter-
val = −1.372 to - 0.1415). (b) Time course of p-Tau, PrPC and
K280Tau-(ac) expression in FHB1 and FH10 (Y218N) at 15, 21 and 45
DIV. Actin was used as control loading protein. (c) Graph of the densi-
tometric values of p-Tau levels of (b). Plots show mean ± S.E.M. of three
different experiments. Note the increase in p-Tau between Y218N and
control cells. (d) High power photomicrographs illustrating MAP2
(green), p-Tau (red) in FHB1 and FH10 (Y218N) neural cultures. A high
magnification of a labelled cell is showed in (f). (e-f) Quantification of
CTCF values derived from experiments in (d). Plots showmean ± S.E.M.
of four different experiments. Asterisks in (e) indicate statistical differ-
ences between groups and controls. **** P < 0.001; Mann-Whitney U
test. Scale bars in d = 50 μm and f = 10 μm
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The deposition of hyperphosphorylated forms of Tau (p-Tau)
has been described in familial and sporadic forms of prion
diseases and in the brains of patients with variant CJD.
Elevated levels of Tau (p-Tau and total Tau) have also been
Fig. 5 FH10 (Y218N) cultures showed impaired mitochondria
displacement. (a) Time-lapse fluorescence photomicrographs illustrating
mitochondria movement in FHB1- (upper panels) and FH10 (Y218N)-
(lower panels) derived neurons. The movement of two mitochondria (ar-
row and open arrow in (a) can be seen in the time lapse panels. (b) Plots
illustrating the Minimum and Mean velocity values of tracked mitochon-
dria in both types of cultures (see Methods for details). Notice the strong
decreases in velocity in FH10 (Y218N)-derived cultures. Plots show
mean ± S.E.M. of three different differentiation experiments.
***P < 0.01, ** P < 0.05. Mann Whitney U test. Scale bar: a = 2.5 μm
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reported in the cerebrospinal fluid (CSF) of patients with spo-
radic CJD [67]. In addition, rodents infected with BSE [68],
263 K [69] and human CJD [70] derived inocula also showed
elevated levels of p-Tau. Indeed, neurons in encephalopathy-
affected brain regions displaying PrP aggregates showed rele-
vant Tau redistribution with increased perinuclear location. This
perinuclear Tau reorganization was observed in CJD- andGSS-
treated Y218N-derived neurons in this study. In this matter, it is
Fig. 6 Infectivity assay with brain inoculates. (a) Schematic
representation of the inoculation protocol: infective brain homogenates
were added at day 0 and day 3 and removed at day 10; cells were
subsequently passaged several times to remove the inocula. (b) Inocula
from the sources (10% of brain homogenates, see Methods for details)
were processed to show PK-resistant PrP signal. GSS: human brain diag-
nosed of Y218N. CJD: human brain diagnosed of a sporadic CJD MM1.
CJD samples were digested with 10–50 μg/ml of proteinase K (PK) and
subjected to a standard biochemical analysis. GSS sample was treated as
an atypical prion sample (seeMethods). The samples were analyzed using
the monoclonal antibody 3F4.MW:Molecular marker. (c) Representative
examples of Western blot detection of PK-resistant PrP forms following
inoculation with CJD and GSS brain samples. Note that PK-resistant PrP
was only detected (when present) for the first 2 weeks after the infection.
(d) Morphological analyses 2 months later revealed little effect of these
inoculates in control neurons while mutant Y218N cultures (e) showed
fewer neurons with marked cytoplasmic redistribution of Tau signal (b, f,
j) and enhanced immunoreactivity for GFAP. Scale bars: 25 μm
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well known that aggregated prion peptides [71], as well as in-
fectious prions [70], may modulate microtubule dynamics and
stability, which may also in turn implicate Tau distribution. The
increased presence and neuronal redistribution of Tau likely has
a direct effect on the neuropathological process triggered by
prion presence, because PrPC binding to Tau is probably
disrupted by the mutations (at least for P102L PRNP [18]). In
fact, if we consider that Y218N might alter natural PrPC func-
tions associated with Tau, the cellular responses mediated by
sCJD and GSS prions might be exacerbated in the presence of
the Y218N PRNP mutation.
In conclusion, we report here the use of iPS cell-derived
neurons to investigate the putative roles of the Y218N PRNP
mutation in neural differentiation, Tau phosphorylation and
cell death. This approach provides a powerful in vitro system
for functional analysis of pathways regulating PRNP function
in human cortical neurons, cellular mechanisms regulating tau
phosphorylation in these models and for the identification and
testing of candidate disease-modifying compounds.
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